Liver transplantation in a patient with severe cystic fibrosis
https://doi.org/10.31146/2949-4664-apps-2-1-133-141
Abstract
Cystic fibrosis (CF) is a severe progressive hereditary disease associated with mutations in the CFTR gene, characterized by multiple organ pathology, including the upper and lower respiratory tract, gastrointestinal and reproductive tracts, and the endocrine system. Despite new therapy, which significantly increases survival among patients with cystic fibrosis, the development of complications of this disease is still a factor affecting the duration and quality of life. The aim of the study is to demonstrate a clinical case of severe course of cystic fibrosis in a patient with meconium ileus, cystic fibrosis-associated diabetes mellitus, pulmonary and arterial hypertension, cirrhosis, who was under the observation of specialists of the Department of Cystic fibrosis of the Research Clinical Institute of Childhood of the Ministry of Health of the Moscow Region and National Medical Research Center of Transplantology and Artificial Organs named after V. I. Shumakov and underwent death donor liver transplantation. New methods of diagnosis and therapy of complications allow timely detection and control of their course, while maintaining a satisfactory quality of life for the patient
About the Authors
E. K. Zhekaite
Research Clinical Institute of Childhood of the Ministry of Health of the Moscow Region; Research Center for Medical Genetics
Russian Federation
Russian Federation
V. R. Salimov
National Medical Research Center of Transplantology and Artificial Organs named after V. I. Shumakov
Russian Federation
Russian Federation
A. R. Monakhov
National Medical Research Center of Transplantology and Artificial Organs named after V. I. Shumakov; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
References
1. Register of patients with cystic fibrosis in the Russian Federation 2021 / Editors S. A. Krasovsky, M. A. Starinova, A. Yu. Voronkova, E. L. Amelina, N. Yu. Kashirskaya, E. I. Kondratyeva, L. P. Nazarenko. St. Petersburg: Charitable Foundation “Ostrova”, 2023, 81 p. (in Russ.)@@ Регистр пациентов с муковисцидозом в Российской Федерации. 2021 год. / Под редакцией С. А. Красовского, М. А. Стариновой, А. Ю. Воронковой, Е. Л. Амелиной, Н. Ю. Каширской, Е. И. Кондратьевой, Л. П. Назаренко - СПб.: Благотворительный фонд «Острова», 2023, 81 с.
2. Terliesner N., Vogel M., Steighardt A. et al. Cystic-fibrosis related-diabetes (CFRD) is preceded by and associated with growth failure and deteriorating lung function. J Pediatr Endocrinol Metab. 2017 Aug 28;30(8):815-821. doi: 10.1515/jpem-2017-0005.
3. Jacquot J., Delion M., Gangloff S., Braux J., Velard F. Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies. Osteoporos Int. 2016 Apr;27(4):1401-1412. doi: 10.1007/s00198-015-3343-3.
4. Polyakov D. P., Pogodina A. A., Kondrat’eva E. I., Voronkova A. Yu., Petrov A. S. Effect of targeted therapy for cystic fibrosis on course of pediatric chronic rhinosinusitis: first russian experience.Russian Otorhinolaryngology. 2023;22(3):86-92. (in Russ.) doi: 10.18692/1810-4800-2023-3-86-92.@@ Поляков Д. П., Погодина А. А., Кондратьева Е. И., Воронкова А. Ю., Петров А. С. Влияние таргетной терапии муковисцидоза на течение хронического риносинусита у ребенка: первый российский опыт. Российская оториноларингология. 2023;22(3):86-92. doi: 10.18692/1810-4800-2023-3-86-92.
5. Klotter V., Gunchick C., Siemers E., Rath T., Hudel H., Naehrlich L., Roderfeld M., Roeb E. Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study. PLoS One. 2017 Jun 2;12(6): e0178784. doi: 10.1371/journal.pone.0178784.
6. Herrmann U., Dockter G., Lammert F. Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol. 2010 Oct;24(5):585-92. doi: 10.1016/j.bpg.2010.08.003.
7. Lamireau T., Monnereau S., Martin S., Marcotte J. E., Winnock M., Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol. 2004 Dec;41(6):920-5. doi: 10.1016/j.jhep.2004.08.006.
8. Kondratieva E.I., Tsirulnikova O. M., Voronkova A. Y., Malomuzh O. I., Ilyenkova N. A., Kashirskaya N. Y., Sherman V. D. Cirrhosis and liver transplantation experience in children and adolescents with cystic fibrosis. Pediatria. 2017; 96 (6): 36-47. (in Russ.) doi: 10.24110/0031-403X-2017-96-6-36-47.@@ Кондратьева Е. И., Цирульникова О. М., Воронкова А. Ю., Маломуж О. И., Ильенкова Н. А., Каширская Н. Ю., Шерман В. Д. Цирроз и опыт трансплантации печени у детей и подростков при муковисцидозе. Педиатрия. 2017; 96 (6): 36-47. doi: 10.24110/0031-403X-2017-96-6-36-47.
9. Kondratyeva E.I., Ilenkova N. A., Chikunov V. V. et al. Health status of cystic fibrosis patients with liver cirrhosis and after liver transplantation. Vopr. prakt. pediatr. (Clinical Practice in Pediatrics). 2022; 17(3): 65-73. (In Russ.) doi: 10.20953/1817-7646-2022-3-65-73.@@ Кондратьева Е. И., Ильенкова Н. А., Чикунов В. В. и соавт. Состояние здоровья пациентов с циррозом печени при муковисцидозе и после трансплантации. Вопросы практической педиатрии. 2022; 17(3): 65-73. doi: 10.20953/1817-7646-2022-3-65-73.
10. Union of Pediatricians of Russia; Association of Medical Genetics; Russian Respiratory Society; Russian Transplant Society; Association of Children’s Doctors of the Moscow Region. [Cystic fibrosis. Clinical guidelines]. 2021. ID: 372. (in Russ.)@@ Клинические рекомендации по кистозному фиброзу (муковисцидозу) 2021 г.
Review
For citations:
Zhekaite E.K., Salimov V.R., Monakhov A.R. Liver transplantation in a patient with severe cystic fibrosis. Archives of Pediatrics and Pediatric Surgery. 2024;2(1):133-141. (In Russ.) https://doi.org/10.31146/2949-4664-apps-2-1-133-141
Views:
206
Email this article 